- Home
- MCN vs NYXH Comparison
MCN vs NYXH Comparison
Compare MCN & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCN | NYXH |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | Canada | Belgium |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.0M | 126.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MCN | NYXH |
|---|---|---|
| Price | $5.79 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | ★ 61.6K | 35.7K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 9.96% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.65 | $2.68 |
| 52 Week High | $6.39 | $8.59 |
Technical Indicators
Market Signals| Indicator | MCN | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 37.68 | 19.11 |
| Support Level | $5.65 | N/A |
| Resistance Level | $6.02 | $5.02 |
| Average True Range (ATR) | 0.07 | 0.16 |
| MACD | -0.00 | -0.09 |
| Stochastic Oscillator | 14.22 | 4.35 |
Price Performance
Historical ComparisonAbout MCN Madison Covered Call & Equity Strategy Fund
XAI Madison Equity Premium Income Fund is an investment management company. The Fund invests in an actively managed equity portfolio comprised of individual stocks and covered call options. The Fund's primary investment objective is to provide high level of current income and gains, with a secondary objective of capital appreciation.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.